HRP20201211T1 - Derivat dihidropiridazin-3,5-diona - Google Patents
Derivat dihidropiridazin-3,5-diona Download PDFInfo
- Publication number
- HRP20201211T1 HRP20201211T1 HRP20201211TT HRP20201211T HRP20201211T1 HR P20201211 T1 HRP20201211 T1 HR P20201211T1 HR P20201211T T HRP20201211T T HR P20201211TT HR P20201211 T HRP20201211 T HR P20201211T HR P20201211 T1 HRP20201211 T1 HR P20201211T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkoxy
- alkyl
- optionally substituted
- substituents
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Luminescent Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013051082 | 2013-03-13 | ||
| JP2013132889 | 2013-06-25 | ||
| PCT/JP2014/056778 WO2014142273A1 (ja) | 2013-03-13 | 2014-03-13 | ジヒドロピリダジン－３，５－ジオン誘導体 |
| EP14765619.3A EP2975030B1 (en) | 2013-03-13 | 2014-03-13 | Dihydropyridazine-3,5-dione derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201211T1 true HRP20201211T1 (hr) | 2020-11-13 |
Family
ID=51536921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201211TT HRP20201211T1 (hr) | 2013-03-13 | 2014-03-13 | Derivat dihidropiridazin-3,5-diona |
Country Status (29)
| Country | Link |
|---|---|
| EP (2) | EP3757093A1 (enExample) |
| JP (2) | JP5814488B2 (enExample) |
| KR (2) | KR102072268B1 (enExample) |
| CN (1) | CN105073715B (enExample) |
| AU (1) | AU2014230552B2 (enExample) |
| BR (1) | BR112015022092B1 (enExample) |
| CA (1) | CA2901868C (enExample) |
| CL (1) | CL2015002543A1 (enExample) |
| CR (1) | CR20150505A (enExample) |
| DK (1) | DK2975030T3 (enExample) |
| ES (1) | ES2811126T3 (enExample) |
| HR (1) | HRP20201211T1 (enExample) |
| HU (1) | HUE050577T2 (enExample) |
| IL (1) | IL240825B (enExample) |
| LT (1) | LT2975030T (enExample) |
| MX (1) | MX376532B (enExample) |
| MY (1) | MY174269A (enExample) |
| NZ (1) | NZ711182A (enExample) |
| PE (1) | PE20151535A1 (enExample) |
| PH (1) | PH12015501940A1 (enExample) |
| PL (1) | PL2975030T3 (enExample) |
| PT (1) | PT2975030T (enExample) |
| RS (1) | RS60911B1 (enExample) |
| RU (1) | RU2662832C2 (enExample) |
| SG (1) | SG11201507345RA (enExample) |
| SI (1) | SI2975030T1 (enExample) |
| TW (2) | TWI596095B (enExample) |
| UA (1) | UA118755C2 (enExample) |
| WO (1) | WO2014142273A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ711182A (en) * | 2013-03-13 | 2020-05-29 | Chugai Pharmaceutical Co Ltd | Dihydropyridazine-3,5-dione derivative |
| BR112017004595A2 (pt) * | 2014-09-12 | 2017-12-05 | Chugai Pharmaceutical Co Ltd | composição farmacêutica contendo inibidor de transportador de fosfato dependente de sódio |
| WO2018019721A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
| WO2018019755A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
| CN110885290A (zh) * | 2019-12-16 | 2020-03-17 | 阿里生物新材料（常州）有限公司 | 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法 |
| WO2021261563A1 (ja) | 2020-06-26 | 2021-12-30 | 日本農薬株式会社 | アリールテトラヒドロピリダジン誘導体又はその塩類及び該化合物を含有する殺虫剤並びにその使用方法 |
| WO2022221182A1 (en) * | 2021-04-12 | 2022-10-20 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc34a1 function |
| CA3221186A1 (en) | 2021-06-08 | 2022-12-15 | Kenichi Sakai | Formulation containing dihydropyridazine-3,5-dione derivative |
| AR126060A1 (es) | 2021-06-08 | 2023-09-06 | Chugai Pharmaceutical Co Ltd | Método para producir derivado de dihidropiridazin-3,5-diona |
| AU2022427156B2 (en) * | 2021-12-28 | 2025-12-11 | Nihon Nohyaku Co., Ltd. | Aryltetrahydropyridazine derivative or salt thereof and insecticidal agent containing the compound and method for using same |
| WO2023219127A1 (ja) | 2022-05-11 | 2023-11-16 | 中外製薬株式会社 | 嚢胞性疾患を治療または予防するための医薬組成物 |
| CN116217862A (zh) * | 2023-03-21 | 2023-06-06 | 中国农业科学院农业环境与可持续发展研究所 | 一种可降解生物膜助剂的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7402580B2 (en) * | 2002-02-19 | 2008-07-22 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
| CN1662529A (zh) * | 2002-06-19 | 2005-08-31 | 默克专利有限公司 | 作为磷酸二酯酶iv抑制剂的噻唑衍生物 |
| CN102898364A (zh) * | 2005-05-18 | 2013-01-30 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| EA017900B1 (ru) * | 2006-11-03 | 2013-04-30 | Басф Се | Способ получения дифторметилпиразолилкарбоксилатов |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| US8217043B2 (en) * | 2008-08-20 | 2012-07-10 | Fibrogen, Inc. | Compounds and methods for their use |
| WO2011048611A1 (en) | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| EP2565190B1 (en) | 2010-04-28 | 2015-06-03 | Astellas Pharma Inc. | Tetrahydrobenzothiophene compound |
| EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP5827327B2 (ja) * | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| CN103906741B (zh) | 2011-10-27 | 2016-01-20 | 安斯泰来制药株式会社 | 氨烷基取代的n-噻吩基苯甲酰胺衍生物 |
| NZ711182A (en) * | 2013-03-13 | 2020-05-29 | Chugai Pharmaceutical Co Ltd | Dihydropyridazine-3,5-dione derivative |
-
2014
- 2014-03-13 NZ NZ711182A patent/NZ711182A/en unknown
- 2014-03-13 CN CN201480013485.6A patent/CN105073715B/zh active Active
- 2014-03-13 BR BR112015022092-4A patent/BR112015022092B1/pt active IP Right Grant
- 2014-03-13 MY MYPI2015703054A patent/MY174269A/en unknown
- 2014-03-13 TW TW103109058A patent/TWI596095B/zh active
- 2014-03-13 UA UAA201509770A patent/UA118755C2/uk unknown
- 2014-03-13 DK DK14765619.3T patent/DK2975030T3/da active
- 2014-03-13 WO PCT/JP2014/056778 patent/WO2014142273A1/ja not_active Ceased
- 2014-03-13 PL PL14765619T patent/PL2975030T3/pl unknown
- 2014-03-13 SI SI201431629T patent/SI2975030T1/sl unknown
- 2014-03-13 CA CA2901868A patent/CA2901868C/en active Active
- 2014-03-13 HU HUE14765619A patent/HUE050577T2/hu unknown
- 2014-03-13 AU AU2014230552A patent/AU2014230552B2/en active Active
- 2014-03-13 PT PT147656193T patent/PT2975030T/pt unknown
- 2014-03-13 LT LTEP14765619.3T patent/LT2975030T/lt unknown
- 2014-03-13 EP EP20185235.7A patent/EP3757093A1/en active Pending
- 2014-03-13 KR KR1020167027514A patent/KR102072268B1/ko active Active
- 2014-03-13 HR HRP20201211TT patent/HRP20201211T1/hr unknown
- 2014-03-13 PE PE2015001917A patent/PE20151535A1/es unknown
- 2014-03-13 KR KR1020157029079A patent/KR101664460B1/ko active Active
- 2014-03-13 RU RU2015143507A patent/RU2662832C2/ru active
- 2014-03-13 SG SG11201507345RA patent/SG11201507345RA/en unknown
- 2014-03-13 RS RS20201171A patent/RS60911B1/sr unknown
- 2014-03-13 JP JP2015505576A patent/JP5814488B2/ja active Active
- 2014-03-13 ES ES14765619T patent/ES2811126T3/es active Active
- 2014-03-13 TW TW106123450A patent/TWI683811B/zh active
- 2014-03-13 MX MX2015012537A patent/MX376532B/es active IP Right Grant
- 2014-03-13 EP EP14765619.3A patent/EP2975030B1/en active Active
-
2015
- 2015-08-25 IL IL240825A patent/IL240825B/en active IP Right Grant
- 2015-09-03 PH PH12015501940A patent/PH12015501940A1/en unknown
- 2015-09-09 CL CL2015002543A patent/CL2015002543A1/es unknown
- 2015-09-16 JP JP2015182722A patent/JP6420738B2/ja active Active
- 2015-09-22 CR CR20150505A patent/CR20150505A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170311T1 (hr) | Novi spojevi pirolopirimidina kao inhibitori protein kinaza | |
| RU2015143507A (ru) | Производное дигидропиридазин-3,5-диона | |
| HRP20240161T1 (hr) | Inhibitor atr i njegova primjena | |
| JP2022548568A5 (enExample) | ||
| HRP20211722T1 (hr) | Supstituirani spojevi pirazolo[1,5-a]pirimidina kao inhibitori trk kinaze | |
| HRP20180037T1 (hr) | Heterociklični spoj koji sadrži dušik ili njegovu sol | |
| HRP20120656T1 (hr) | Derivati indazolil amida za liječenje poremećaja posredovanih glukokortikoidnim receptorom | |
| NZ589843A (en) | Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors | |
| HRP20080592T3 (en) | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | |
| JP2013523710A5 (enExample) | ||
| JP2014139226A5 (enExample) | ||
| ME02452B (me) | Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti | |
| HRP20161547T1 (hr) | Derivati 5-fluor-n-(piridin-2-il)piridin-2-amina koji sadrže sulfoksiminsku skupinu | |
| HRP20171999T1 (hr) | Novi derivati aminopirimidina | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| GEP20156250B (en) | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 | |
| EA201070395A1 (ru) | Ингибиторы polo-подобных киназ | |
| HRP20060100T3 (en) | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto | |
| HRP20192274T1 (hr) | Novi derivati oktahidro-pirolo[3,4−c]-pirola i njihovi analozi kao inhibitori autotaksina | |
| ME02855B (me) | KONDENZOVANI TETRA ILl PENTA-CIKLIČNI DIHIDRODIAZEPINOKARBAZOLONI KAO PARP INHIBITORI | |
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| MA38072A1 (fr) | Composés hétérocycliques substitués par amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifn? | |
| HRP20150427T1 (hr) | Ne-nukleozidni inhibitori reverzne transkriptaze | |
| NZ613235A (en) | Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors | |
| JP2017511794A5 (enExample) |